Page 127 - 《中国药房》2021年10期

Chinese patients with chronic hepatitis C virus infec- and without cirrhosis[J]. J Gastroenterol，2018，53（4）：
tion[J]. J Gastroenterol Hepatol，2014，29（3）：545-553. 557-565.
[ 4 ] CHEN Y，YU C，YIN X，et al. Hepatitis C virus genotypes [16] CURRY M P，O’LEARY J G，BZOWEJ N，et al. Sofosbu-
and subtypes circulating in mainland China[J]. Emerg Mi- vir and velpatasvir for HCV in patients with decompensa-
crobes Infect，2017，6（11）：e95. ted cirrhosis[J]. N Engl J Med，2015，373（27）：2618-2628.
[ 5 ] World Health Organization. Guidelines for the care and [17] DE LÉDINGHEN V，LAFOREST C，HÉZODE C，et al.
treatment of persons diagnosed with chronic hepatitis C vi- Retreatment with sofosbuvir plus grazoprevir/elbasvir
rus infection：2018[EB/OL]. [2021-04-15]. https：//apps. plus ribavirin of patients with hepatitis C virus genotype
who.int/iris/handle/10665/273174. 1 or 4 who previously failed an ns5a-or ns3-containing
[ 6 ] PECORARO V，BANZI R，CARIANI E，et al. New direc- regimen：the anrs HC34 revenge study[J]. Clin Infect Dis，
tacting antivirals for the treatment of patients with hepatitis 2018，66（7）：1013-1018.
C virus infection：a systematic review of randomized con- [18] ESTEBAN R，PINEDA J A，CALLEJA J L，et al. Efficacy
trolled trials[J]. J Clin Exp Hepatol，2019，9（4）：522-538. of sofosbuvir and velpatasvir，with and without ribavirin，
[ 7 ] 温晓玉，牛俊奇.直接抗病毒药物治疗慢性丙型肝炎的作 in patients with hepatitis C virus genotype 3 infection and
用机制[J].临床肝胆病杂志，2016，32（9）：1699-1705. cirrhosis[J]. Gastroenterology，2018，155（4）：1120-1127.
[ 8 ] AFDHAL N，REDDY K R，NELSON D R，et al. Ledipas- [19] EVERSON G T，TOWNER W J，DAVIS M N，et al. So-
vir and sofosbuvir for previously treated HCV genotype 1 fosbuvir with velpatasvir in treatment-naive noncirrhotic
infection[J]. N Engl J Med，2014，370（16）：1483-1493. patients with genotype 1 to 6 hepatitis C virus infection：a
[ 9 ] AFDHAL N，ZEUZEM S，KWO P，et al. Ledipasvir and randomized trial[J]. Ann Intern Med，2015，163（11）：818-
sofosbuvir for untreated HCV genotype 1 infection[J]. N 826.
Engl J Med，2014，370（20）：1889-1898. [20] FELD J J，JACOBSON I M，HÉZODE C，et al. Sofosbu-
[10] ASAHINA Y，ITOH Y，UENO Y，et al. Ledipasvir-sofos- vir and velpatasvir for HCV genotype 1，2，4，5，and 6 in-
buvir for treating Japanese patients with chronic hepatitis fection[J]. N Engl J Med，2015，373（27）：2599-2607.
C virus genotype 2 infection[J]. Liver Int，2018，38（9）： [21] FELD J J，JACOBSON I M，JENSEN D M，et al. Ran-
1552-1561. domized study of danoprevir/ritonavir-based therapy for
[11] ASSELAH T，KOWDLEY K V，ZADEIKIS N，et al. Effi- HCV genotype 1 patients with prior partial or null respon-
cacy of glecaprevir/pibrentasvir for 8 or 12 weeks in pa- ses to peginterferon/ribavirin[J]. J Hepatol，2015，62（2）：
tients with hepatitis C virus genotype 2，4，5，or 6 infec- 294-302.
tion without cirrhosis[J]. Clin Gastroenterol Hepatol， [22] FOSTER G R，AFDHAL N，ROBERTS S K，et al. Sofos-
2018，16（3）：417-426. buvir and velpatasvir for HCV genotype 2 and 3 infec-
[12] BOURLIÈRE M，GORDON S C，FLAMM S L，et al. So- tion[J]. N Engl J Med，2015，373（27）：2608-2617.
fosbuvir，Velpatasvir，and voxilaprevir for previously trea- [23] FOSTER G R，AGARWAL K，CRAMP M E，et al. Elbas-
ted HCV infection[J]. N Engl J Med，2017，376（22）： vir/grazoprevir and sofosbuvir for hepatitis C virus geno-
2134-2146. type 3 infection with compensated cirrhosis：a randomized
[13] BROWN A，HÉZODE C，ZUCKERMAN E，et al. Effica- trial[J]. Hepatology，2018，67（6）：2113-2126.
cy and safety of 12 weeks of elbasvir±grazoprevir±riba- [24] GANE E J，HYLAND R H，AN D，et al. Efficacy of ledi-
virin in participants with hepatitis C virus genotype 2，4， pasvir and sofosbuvir，with or without ribavirin，for 12
5 or 6 infection：the C-SCAPE study[J]. J Viral Hepat， weeks in patients with HCV genotype 3 or 6 infection[J].
2018，25（5）：457-464. Gastroenterology，2015，149（6）：1454-1461.
[14] CHARLTON M，EVERSON G T，FLAMM S L，et al. Le- [25] GANE E J，POCKROS P J，ZEUZEM S，et al. Mericita-
dipasvir and sofosbuvir plus ribavirin for treatment of bine and ritonavir-boosted danoprevir with or without riba-
HCV infection in patients with advanced liver disease[J]. virin in treatment-naive HCV genotype 1 patients：
Gastroenterology，2015，149（3）：649-659. INFORM-SVR study[J]. Liver Int，2015，35（1）：79-89.
[15] CHAYAMA K，SUZUKI F，KARINO Y，et al. Efficacy [26] GANE E J，STEDMAN C A，HYLAND R H，et al. Effica-
and safety of glecaprevir/pibrentasvir in Japanese patients cy of nucleotide polymerase inhibitor sofosbuvir plus the
with chronic genotype 1 hepatitis C virus infection with NS5A inhibitor ledipasvir or the NS5B non-nucleoside in-

中国药房 2021年第32卷第10期 China Pharmacy 2021 Vol. 32 No. 10 ·1269 ·